FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318539883> ?p ?o ?g. }

• W4318539883 endingPage "i126" @default.
• W4318539883 startingPage "i124" @default.
• W4318539883 abstract "Abstract Background Patients with moderately to severely active luminal Crohn’s disease (CD) have a high inflammatory burden, which can result in irreversible complications and therefore require urgent treatment. However, the speed of onset of efficacy of advanced agents is unclear. Therefore, we aimed to assess the onset of efficacy of biological therapies and small molecules for this adult patient population. Methods For this systematic review and network meta-analysis, we searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials between inception and Sep 10, 2022. We included original data from randomized clinical trials and open-label interventional studies. The co-primary outcomes were clinical response, defined as i) ≥70-point or ii) ≥100-point reduction in Crohn’s Disease Activity Index (CDAI-70 and CDAI-100) from baseline, and clinical remission, defined as CDAI ≤ 150 at week 2. Network meta-analysis was conducted under the Bayesian framework. This study is registered with PROSPERO: CRD42022368509. Results Of 10,129 and 19,281 studies from databases and congress proceedings, 61 studies comprising 17,436 patients were eligible for this study. Adalimumab 160/80 mg, adalimumab 80/40 mg, and certolizumab 400 mg were evaluated for the induction of a CDAI-70 and CDAI-100 response at week 2 and were all superior to placebo. Further, data on upadacitinib 45 mg once daily, vedolizumab 300 mg, and ustekinumab 6 mg/kg were reported for CDAI-100 response at week 2, with the former ranking highest and the latter ranking lowest. Of note, vedolizumab 300 mg did not achieve statistical superiority compared to placebo. However, no statistically significant difference between the agents was found (Figure 1). Further, the biosimilar BI 69550 160/80 mg and adalimumab 160/80 mg ranked highest and were superior to filgotinib 200 mg for achieving CDAI remission at week 2 (Figure 2). The latter ranked lowest and was, along with vedolizumab 300 mg, not superior to placebo for achieving CDAI remission at week 2 (Figure 2). Findings were consistent in the sensitivity analysis for bio-naïve and bio-exposed patients. However, in the sensitivity analysis of efficacy at week 4 in bio-exposed patients, ustekinumab 6 mg/kg ranked highest for both CDAI-70 and CDAI-100 responses (Figure 3). Sensitivity analysis on modes of action did not yield statistically significant differences. Conclusion In this network meta-analysis, we found adalimumab 160/80 mg and upadacitinib 45 mg to be the preferred agents for rapid induction of clinical response and clinical remission at week 2, while vedolizumab 300 mg, filgotinib 200 mg, and ustekinumab 6 mg/kg might have a relatively slower onset of effect in this patient population." @default.
• W4318539883 created "2023-01-31" @default.
• W4318539883 creator A5008566468 @default.
• W4318539883 creator A5014880755 @default.
• W4318539883 creator A5016602166 @default.
• W4318539883 creator A5023920091 @default.
• W4318539883 creator A5038540414 @default.
• W4318539883 creator A5054819282 @default.
• W4318539883 date "2023-01-30" @default.
• W4318539883 modified "2023-09-27" @default.
• W4318539883 title "DOP54 Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn’s disease – a systematic review and network meta-analysis" @default.
• W4318539883 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0094" @default.
• W4318539883 hasPublicationYear "2023" @default.
• W4318539883 type Work @default.
• W4318539883 citedByCount "0" @default.
• W4318539883 crossrefType "journal-article" @default.
• W4318539883 hasAuthorship W4318539883A5008566468 @default.
• W4318539883 hasAuthorship W4318539883A5014880755 @default.
• W4318539883 hasAuthorship W4318539883A5016602166 @default.
• W4318539883 hasAuthorship W4318539883A5023920091 @default.
• W4318539883 hasAuthorship W4318539883A5038540414 @default.
• W4318539883 hasAuthorship W4318539883A5054819282 @default.
• W4318539883 hasBestOaLocation W43185398831 @default.
• W4318539883 hasConcept C126322002 @default.
• W4318539883 hasConcept C142724271 @default.
• W4318539883 hasConcept C168563851 @default.
• W4318539883 hasConcept C203092338 @default.
• W4318539883 hasConcept C204787440 @default.
• W4318539883 hasConcept C27081682 @default.
• W4318539883 hasConcept C2776207728 @default.
• W4318539883 hasConcept C2776478404 @default.
• W4318539883 hasConcept C2778975655 @default.
• W4318539883 hasConcept C2779134260 @default.
• W4318539883 hasConcept C2779280984 @default.
• W4318539883 hasConcept C2780132546 @default.
• W4318539883 hasConcept C2908647359 @default.
• W4318539883 hasConcept C535046627 @default.
• W4318539883 hasConcept C71924100 @default.
• W4318539883 hasConcept C95190672 @default.
• W4318539883 hasConcept C99454951 @default.
• W4318539883 hasConceptScore W4318539883C126322002 @default.
• W4318539883 hasConceptScore W4318539883C142724271 @default.
• W4318539883 hasConceptScore W4318539883C168563851 @default.
• W4318539883 hasConceptScore W4318539883C203092338 @default.
• W4318539883 hasConceptScore W4318539883C204787440 @default.
• W4318539883 hasConceptScore W4318539883C27081682 @default.
• W4318539883 hasConceptScore W4318539883C2776207728 @default.
• W4318539883 hasConceptScore W4318539883C2776478404 @default.
• W4318539883 hasConceptScore W4318539883C2778975655 @default.
• W4318539883 hasConceptScore W4318539883C2779134260 @default.
• W4318539883 hasConceptScore W4318539883C2779280984 @default.
• W4318539883 hasConceptScore W4318539883C2780132546 @default.
• W4318539883 hasConceptScore W4318539883C2908647359 @default.
• W4318539883 hasConceptScore W4318539883C535046627 @default.
• W4318539883 hasConceptScore W4318539883C71924100 @default.
• W4318539883 hasConceptScore W4318539883C95190672 @default.
• W4318539883 hasConceptScore W4318539883C99454951 @default.
• W4318539883 hasIssue "Supplement_1" @default.
• W4318539883 hasLocation W43185398831 @default.
• W4318539883 hasOpenAccess W4318539883 @default.
• W4318539883 hasPrimaryLocation W43185398831 @default.
• W4318539883 hasRelatedWork W2414272582 @default.
• W4318539883 hasRelatedWork W2984488335 @default.
• W4318539883 hasRelatedWork W2994610731 @default.
• W4318539883 hasRelatedWork W2999567714 @default.
• W4318539883 hasRelatedWork W3198525943 @default.
• W4318539883 hasRelatedWork W3201963472 @default.
• W4318539883 hasRelatedWork W4316086302 @default.
• W4318539883 hasRelatedWork W4318539104 @default.
• W4318539883 hasRelatedWork W4353047497 @default.
• W4318539883 hasRelatedWork W4381125750 @default.
• W4318539883 hasVolume "17" @default.
• W4318539883 isParatext "false" @default.
• W4318539883 isRetracted "false" @default.
• W4318539883 workType "article" @default.